Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
Identifieur interne : 003716 ( PascalFrancis/Curation ); précédent : 003715; suivant : 003717Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
Auteurs : John R. Perfect [États-Unis, Royaume-Uni] ; William E. Dismukes [États-Unis] ; Francoise Dromer ; David L. Goldman [États-Unis] ; John R. Graybill [États-Unis] ; Richard J. Hamill [États-Unis] ; Thomas S. Harrison ; Robert A. Larsen [États-Unis] ; Olivier Lortholary ; Minh-Hong Nguyen [États-Unis] ; Peter G. Pappas [États-Unis] ; William G. Powderly ; Nina Singh ; Jack D. Sobel ; Tania C. SorrellSource :
- Clinical infectious diseases [ 1058-4838 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Recommandation.
English descriptors
- KwdEn :
Abstract
Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002870
Links to Exploration step
Pascal:10-0096367Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America</title><author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R." last="Perfect">John R. Perfect</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Infectious Diseases, Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Infectious Diseases Section, VA Medical Center</s1><s2>Pittsburgh, Pennsylvania</s2><s3>USA</s3></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Department of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Dismukes, William E" sort="Dismukes, William E" uniqKey="Dismukes W" first="William E." last="Dismukes">William E. Dismukes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, University of Alabama</s1><s2>Birmingham</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Dromer, Francoise" sort="Dromer, Francoise" uniqKey="Dromer F" first="Francoise" last="Dromer">Francoise Dromer</name></author><author><name sortKey="Goldman, David L" sort="Goldman, David L" uniqKey="Goldman D" first="David L." last="Goldman">David L. Goldman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatric Infectious Diseases, Albert Einstein College of Medicine</s1><s2>Bronx, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Graybill, John R" sort="Graybill, John R" uniqKey="Graybill J" first="John R." last="Graybill">John R. Graybill</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, University of Texas San Antonio, Audie L. Murphy Veterans Affairs Hospital</s1><s2>San Antonio</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hamill, Richard J" sort="Hamill, Richard J" uniqKey="Hamill R" first="Richard J." last="Hamill">Richard J. Hamill</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Division of Infectious Diseases, Veteran's Affairs (VA) Medical Center</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Harrison, Thomas S" sort="Harrison, Thomas S" uniqKey="Harrison T" first="Thomas S." last="Harrison">Thomas S. Harrison</name></author><author><name sortKey="Larsen, Robert A" sort="Larsen, Robert A" uniqKey="Larsen R" first="Robert A." last="Larsen">Robert A. Larsen</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicine, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Infectious Diseases, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Lortholary, Olivier" sort="Lortholary, Olivier" uniqKey="Lortholary O" first="Olivier" last="Lortholary">Olivier Lortholary</name></author><author><name sortKey="Nguyen, Minh Hong" sort="Nguyen, Minh Hong" uniqKey="Nguyen M" first="Minh-Hong" last="Nguyen">Minh-Hong Nguyen</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Division of Infectious Diseases, University of Pittsburgh College of Medicine</s1><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Pappas, Peter G" sort="Pappas, Peter G" uniqKey="Pappas P" first="Peter G." last="Pappas">Peter G. Pappas</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, University of Alabama</s1><s2>Birmingham</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Powderly, William G" sort="Powderly, William G" uniqKey="Powderly W" first="William G." last="Powderly">William G. Powderly</name></author><author><name sortKey="Singh, Nina" sort="Singh, Nina" uniqKey="Singh N" first="Nina" last="Singh">Nina Singh</name></author><author><name sortKey="Sobel, Jack D" sort="Sobel, Jack D" uniqKey="Sobel J" first="Jack D." last="Sobel">Jack D. Sobel</name></author><author><name sortKey="Sorrell, Tania C" sort="Sorrell, Tania C" uniqKey="Sorrell T" first="Tania C." last="Sorrell">Tania C. Sorrell</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0096367</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0096367 INIST</idno><idno type="RBID">Pascal:10-0096367</idno><idno type="wicri:Area/PascalFrancis/Corpus">002870</idno><idno type="wicri:Area/PascalFrancis/Curation">003716</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America</title><author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R." last="Perfect">John R. Perfect</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Infectious Diseases, Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Infectious Diseases Section, VA Medical Center</s1><s2>Pittsburgh, Pennsylvania</s2><s3>USA</s3></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Department of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Dismukes, William E" sort="Dismukes, William E" uniqKey="Dismukes W" first="William E." last="Dismukes">William E. Dismukes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, University of Alabama</s1><s2>Birmingham</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Dromer, Francoise" sort="Dromer, Francoise" uniqKey="Dromer F" first="Francoise" last="Dromer">Francoise Dromer</name></author><author><name sortKey="Goldman, David L" sort="Goldman, David L" uniqKey="Goldman D" first="David L." last="Goldman">David L. Goldman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatric Infectious Diseases, Albert Einstein College of Medicine</s1><s2>Bronx, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Graybill, John R" sort="Graybill, John R" uniqKey="Graybill J" first="John R." last="Graybill">John R. Graybill</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, University of Texas San Antonio, Audie L. Murphy Veterans Affairs Hospital</s1><s2>San Antonio</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hamill, Richard J" sort="Hamill, Richard J" uniqKey="Hamill R" first="Richard J." last="Hamill">Richard J. Hamill</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Division of Infectious Diseases, Veteran's Affairs (VA) Medical Center</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Harrison, Thomas S" sort="Harrison, Thomas S" uniqKey="Harrison T" first="Thomas S." last="Harrison">Thomas S. Harrison</name></author><author><name sortKey="Larsen, Robert A" sort="Larsen, Robert A" uniqKey="Larsen R" first="Robert A." last="Larsen">Robert A. Larsen</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicine, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Infectious Diseases, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Lortholary, Olivier" sort="Lortholary, Olivier" uniqKey="Lortholary O" first="Olivier" last="Lortholary">Olivier Lortholary</name></author><author><name sortKey="Nguyen, Minh Hong" sort="Nguyen, Minh Hong" uniqKey="Nguyen M" first="Minh-Hong" last="Nguyen">Minh-Hong Nguyen</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Division of Infectious Diseases, University of Pittsburgh College of Medicine</s1><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Pappas, Peter G" sort="Pappas, Peter G" uniqKey="Pappas P" first="Peter G." last="Pappas">Peter G. Pappas</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, University of Alabama</s1><s2>Birmingham</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Powderly, William G" sort="Powderly, William G" uniqKey="Powderly W" first="William G." last="Powderly">William G. Powderly</name></author><author><name sortKey="Singh, Nina" sort="Singh, Nina" uniqKey="Singh N" first="Nina" last="Singh">Nina Singh</name></author><author><name sortKey="Sobel, Jack D" sort="Sobel, Jack D" uniqKey="Sobel J" first="Jack D." last="Sobel">Jack D. Sobel</name></author><author><name sortKey="Sorrell, Tania C" sort="Sorrell, Tania C" uniqKey="Sorrell T" first="Tania C." last="Sorrell">Tania C. Sorrell</name></author></analytic><series><title level="j" type="main">Clinical infectious diseases</title><title level="j" type="abbreviated">Clin. infect. dis.</title><idno type="ISSN">1058-4838</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical infectious diseases</title><title level="j" type="abbreviated">Clin. infect. dis.</title><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>America</term><term>Clinical management</term><term>Cryptococcosis</term><term>Infection</term><term>Recommendation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Infection</term><term>Conduite à tenir</term><term>Recommandation</term><term>Cryptococcose</term><term>Amérique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1058-4838</s0></fA01><fA02 i1="01"><s0>CIDIEL</s0></fA02><fA03 i2="1"><s0>Clin. infect. dis.</s0></fA03><fA05><s2>50</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America</s1></fA08><fA11 i1="01" i2="1"><s1>PERFECT (John R.)</s1></fA11><fA11 i1="02" i2="1"><s1>DISMUKES (William E.)</s1></fA11><fA11 i1="03" i2="1"><s1>DROMER (Francoise)</s1></fA11><fA11 i1="04" i2="1"><s1>GOLDMAN (David L.)</s1></fA11><fA11 i1="05" i2="1"><s1>GRAYBILL (John R.)</s1></fA11><fA11 i1="06" i2="1"><s1>HAMILL (Richard J.)</s1></fA11><fA11 i1="07" i2="1"><s1>HARRISON (Thomas S.)</s1></fA11><fA11 i1="08" i2="1"><s1>LARSEN (Robert A.)</s1></fA11><fA11 i1="09" i2="1"><s1>LORTHOLARY (Olivier)</s1></fA11><fA11 i1="10" i2="1"><s1>NGUYEN (Minh-Hong)</s1></fA11><fA11 i1="11" i2="1"><s1>PAPPAS (Peter G.)</s1></fA11><fA11 i1="12" i2="1"><s1>POWDERLY (William G.)</s1></fA11><fA11 i1="13" i2="1"><s1>SINGH (Nina)</s1></fA11><fA11 i1="14" i2="1"><s1>SOBEL (Jack D.)</s1></fA11><fA11 i1="15" i2="1"><s1>SORRELL (Tania C.)</s1></fA11><fA14 i1="01"><s1>Division of Infectious Diseases, Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Division of Infectious Diseases, University of Alabama</s1><s2>Birmingham</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Pediatric Infectious Diseases, Albert Einstein College of Medicine</s1><s2>Bronx, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Division of Infectious Diseases, University of Texas San Antonio, Audie L. Murphy Veterans Affairs Hospital</s1><s2>San Antonio</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Division of Infectious Diseases, Veteran's Affairs (VA) Medical Center</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Medicine, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Infectious Diseases, University of Southern California School of Medicine</s1><s2>Los Angeles</s2><s3>USA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Division of Infectious Diseases, University of Pittsburgh College of Medicine</s1><s3>USA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="09"><s1>Infectious Diseases Section, VA Medical Center</s1><s2>Pittsburgh, Pennsylvania</s2><s3>USA</s3></fA14><fA14 i1="10"><s1>Wayne State University, Harper Hospital</s1><s2>Detroit, Michigan</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="11"><s1>Institut Pasteur, Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moleculaire</s1><s3>FRA</s3><sZ>3 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="12"><s1>Université Paris-Descartes, Service des Maladies Infectieuses et Tropicales, Hôpital Necker-Enfants Malades, Centre d'Infectiologie Necker-Pasteur</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="13"><s1>University College</s1><s2>Dublin</s2><s3>IRL</s3><sZ>12 aut.</sZ></fA14><fA14 i1="14"><s1>Department of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3></fA14><fA14 i1="15"><s1>Centre for Infectious Diseases and Microbiology, University of Sydney at Westmead</s1><s2>Sydney</s2><s3>AUS</s3><sZ>7 aut.</sZ><sZ>15 aut.</sZ></fA14><fA20><s1>291-322</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18407</s2><s5>354000180873050010</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>191 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0096367</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Clinical infectious diseases</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients.</s0></fC01><fC02 i1="01" i2="X"><s0>002B05D02L</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Infection</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Infection</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Infección</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Conduite à tenir</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Clinical management</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Actitud médica</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Recommandation</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Recommendation</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Recomendación</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Cryptococcose</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Cryptococcosis</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Criptococosis</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Amérique</s0><s2>NG</s2><s5>13</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>America</s0><s2>NG</s2><s5>13</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>America</s0><s2>NG</s2><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Mycose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Mycosis</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Micosis</s0></fC07><fN21><s1>060</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003716 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003716 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:10-0096367
|texte= Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
}}
| This area was generated with Dilib version V0.6.33. |  |